COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
J Microsc Ultrastruct
; 8(4): 141-145, 2020.
Article
in English
| MEDLINE | ID: covidwho-1000436
ABSTRACT
COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
J Microsc Ultrastruct
Year:
2020
Document Type:
Article
Affiliation country:
JMAU.JMAU_63_20
Similar
MEDLINE
...
LILACS
LIS